CN103555664B - A kind of method of cultivator placenta mesenchyma stem cell - Google Patents
A kind of method of cultivator placenta mesenchyma stem cell Download PDFInfo
- Publication number
- CN103555664B CN103555664B CN201310579777.3A CN201310579777A CN103555664B CN 103555664 B CN103555664 B CN 103555664B CN 201310579777 A CN201310579777 A CN 201310579777A CN 103555664 B CN103555664 B CN 103555664B
- Authority
- CN
- China
- Prior art keywords
- placenta
- cell
- stem cell
- injection
- culturing bottle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a kind of method of cultivator placenta mesenchyma stem cell.It comprises the steps: the human placenta getting fresh collection, cleaning, puts into placenta protection liquid 2-8 DEG C and saves backup; Get the human placenta being immersed in and being no more than 48 hours in placenta protection liquid; cleaning; put successively again to face and be respectively 2500-3500 with the benzylpenicillin sodium of newly joining and Vetstrep content? U/mL and 3500-4500? is the sodium chloride solution of U/mL and every milliliter containing 30-50? embathe in the Metronidazule injection of U Amphotericin B for injection; last cleaning be again placed on carry out in disposable sterilized culture dish for subsequent use; then be separated, be cultured to cytogamy degree and reach 80-90% and get final product.The potential danger that the present invention can avoid the reagent of animal serum and animal-origin to bring; The cultivation of placenta mesenchyma stem cell is all can be used in 48 hours, workable; Can greatly reduce because mould, anerobe pollute the underproof probability of mescenchymal stem cell separation and Culture caused.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of method of cultivator placenta mesenchyma stem cell.
Background technology
Stem cell is a kind of undifferentiated cell, there are two fundamental characteristics, one is have the of self-replication capacity, two is the functioning cells that can be divided into more than one, according to the size of differentiation potential, stem cell is generally divided into three classes, and the first kind is myeloid-lymphoid stem cell (totipotent stem cell), it can be divided into the consistent totipotent cell of function, can grow for fetus; Equations of The Second Kind is pluripotent stem cell (pturipotent stem cel), and it can be divided into often kind of cell type in health, but can not form placenta or the necessary sustentacular tissue of fetation.Because the differentiation potential of pluripotent stem cell is not " entirety ", therefore this cell is not called " all-round ", and they not to be embryos.The further specialization of pluripotent stem cell is multipotency (multiPotent) stem cell, and it is exclusively used in the cell of the specific germline being divided into specific function specialization.Multipotential stem cell can be divided into the cell type contained in the tissue that they are derived from; Such as blood stem cell is merely able to be divided into red blood cell, white cell and thrombocyte.Embryonic stem cell (Embryonic stem cell) has potential widely, can generate except all histocytes of extraplacental body; 3rd class is adult stem cell (aduit stem cell) is the undifferentiated cell that one will have lifelong self-replacation (identical copies) and self (self-renewal) ability, it is distributed in different tissues, and can develop and become various types of qualification cell.The classification of stem cell, is mainly divided into hemopoietic stem cell and non-hematopoietic stem cell.Hemopoietic stem cell dominates the disease of blood, immunology, such as Cord blood of originating; Non-hematopoietic stem cell then based on cytodifferentiation and reparation, can be applicable to the regenerative medicines such as apoplexy, diabetes, senile dementia, and there are umbilical cord, placenta, deciduous teeth etc. in source.
Mescenchymal stem cell (mesenchymal stem cell MSC) is the multipotential stem cell that can form various kinds of cell type.Mescenchymal stem cell (MSC) finds in marrow, also finds subsequently to be present in the Various Tissues perhaps of human body generation, growth course.In view of mescenchymal stem cell have multi-lineage potential, can hematopoiesis support and promote that hemopoietic stem cell is implanted, immunity moderation and the feature such as separation and Culture is easy and simple to handle, just day by day receive the concern of people.The range of application of mescenchymal stem cell is also more and more extensive.Carried out multinomial clinical application research both at home and abroad at present, principal disease type comprises osteoarthritis disorders, liver cirrhosis, graft host rejection reaction (GVHD), Spinal injury and degenerative neural disease and diabetes etc.
Summary of the invention
Technical problem to be solved by this invention is a kind of method providing cultivator placenta mesenchyma stem cell.
For solving technical problem of the present invention, the technical solution used in the present invention is as follows:
A method for cultivator placenta mesenchyma stem cell, is characterized in that: it comprises the steps:
(1) human placenta of fresh collection is got, cleaning, put into placenta protection liquid 2-8 DEG C to save backup, described placenta protection liquid adds benzylpenicillin sodium in AIM-V substratum and Vetstrep obtains, and wherein benzylpenicillin sodium and the final concentration of Vetstrep in umbilical cord protection liquid are respectively 100-200 U/mL and 100-200 U/mL;
(2) human placenta being immersed in and being no more than 48 hours in placenta protection liquid is got, cleaning, put successively again face be respectively the sodium chloride solution of 2500-3500 U/mL and 3500-4500 U/mL with the benzylpenicillin sodium of newly joining and Vetstrep content and every milliliter embathe containing in the Metronidazule injection of 30-50 U amphotericin B, finally again cleaning be placed on carry out in disposable sterilized culture dish for subsequent use;
(3) aseptic cleaned human placenta is cut into meat gruel shape, adds AIM-V substratum, put in separator tube and be separated with full-automatic separate tissue device, re-use aseptic strainer filtering, obtain placenta tissue cell suspension;
(4) placenta tissue cell suspension is carried out centrifugal, abandon supernatant, collect lower floor, be placed in culturing bottle, then add serum free medium wherein, be placed in 36-38 DEG C, saturated humidity, volume fraction be the CO of 5%
2cultivate in incubator, to observe bottle wall formed multiple not of uniform size, cell island that cell quantity is intensive time, then obtain Human plactnta mescenchymal stem cell primary cell mixed solution, then through centrifugal, Human plactnta mescenchymal stem cell primary cell can be obtained, then reach 80-90% through Secondary Culture to cytogamy degree and get final product.
By such scheme, join again in AIM-V substratum (treatment level) after benzylpenicillin sodium for injection and streptomycin sulphate for injection dissolve by placenta protection liquid in described step (1) in advance and obtain; Benzylpenicillin sodium for injection and streptomycin sulphate for injection are mixed to get by a certain amount of adding in 0.9% sodium chloride injection by the sodium chloride solution that the middle benzylpenicillin sodium of described step (2) and Vetstrep content are respectively 2500-3500 U/mL and 3500-4500 U/mL; Described every milliliter of preparation of Metronidazule injection containing 30-50 U amphotericin B is by Amphotericin B for injection first with after 0.9% sodium chloride injection dissolving, then is mixed to get with a certain amount of Metronidazule injection; Described Human plactnta benzylpenicillin sodium and Vetstrep content be respectively the sodium chloride solution of 2500-3500 U/mL and 3500-4500 U/mL and every milliliter be 8-12min containing the time of embathing in the Metronidazule injection of 30-50 U amphotericin B.
By such scheme, the cleaning in described step (1) and step (2) is 0.9% sodium chloride injection cleaning.
By such scheme, the placenta tissue in described step (1) gets after placenta gives birth to, and gets the tissue block in 3-5cm around umbilical cord attachment area.
By such scheme, not adherent upper strata, for after cultivation 5-6 days, is removed by described step (4), in culturing bottle, then adds serum free medium continue to cultivate, and changed liquid once every 3-4 days, Human plactnta mescenchymal stem cell primary cell can be obtained until cultivation after 10-15 days;
Then the substratum in culturing bottle is shifted out completely, the recombinant animal tryptic phosphate buffered saline buffer submergence attached cell that mass percent is 0.25% is added in culturing bottle, put into 36 ~ 38 DEG C of incubator insulation digestion 7-9 minute, when observing the contracting of attached cell circle, and at the bottom of having departed from bottle after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, centrifugally abandon supernatant, blow the even cell be deposited in bottom centrifuge tube, then according to 4000-6000 cell/cm
2be inoculated in culturing bottle, and supplement serum free medium in culturing bottle, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once, fusion together to attached cell, and degrees of fusion reaches 80-90%, obtains Human plactnta mescenchymal stem cell, whenever necessary, can repeat aforesaid operations and carry out how increasing for cell cultures.
By such scheme, described T25 culturing bottle can place the Human plactnta that is no more than 5g through the process of full-automatic separate tissue device, filtration, centrifugal after lower confluent monolayer cells cultivate; The described T75 culturing bottle Human plactnta that can place 10-15 g through the process of full-automatic separate tissue device, filtration, centrifugal after lower confluent monolayer cells cultivate; The described T175 culturing bottle Human plactnta that can place 30-35 g through the process of full-automatic separate tissue device, filtration, centrifugal after lower confluent monolayer cells cultivate;
The volume of the serum free medium needed in described T25 culturing bottle is 6-8mL; The volume of the serum free medium needed in described T75 culturing bottle is 20-25mL; The volume of the serum free medium needed in described T175 culturing bottle is 30-35mL.
First the separation preparation of Human plactnta mescenchymal stem cell requires that placenta tissue has certain activity, is generally the activity ensureing placenta tissue, need to process in time placenta, and this also brings obstacle to practical application.The present invention preserves by the placenta of fresh collection being placed in placenta protection liquid, can reach the effect to microbial disinfection residual in placenta, can maintain again the object of the activity of placenta tissue.The placenta using placenta of the present invention to protect liquid 2-8 DEG C to carry out preserving all can be used for the cultivation of placenta mesenchyma stem cell in 48 hours, and this brings great operability to actual preparation production.
Except this, the present invention is when carrying out aseptic cleaning to placenta, carry out except aseptically process except using the sodium chloride solution of benzylpenicillin sodium and Vetstrep, the present invention is also especially in conjunction with the self-pollution feature of placenta, especially the Human plactnta that natural labor is collected is subject to the problem of anerobe and mould contamination, with the addition of especially in the Metronidazule injection of Amphotericin B for injection and carry out aseptically process, and the success ratio of Human plactnta mescenchymal stem cell cultivation can be significantly improved thus.Wherein, Metronidazule injection mainly can be used for the treatment of anti anaerobic bacteria infection, anti-trichomonal, Amphotericin B for injection is polyene antifungal medicine, and it can destroy the eubolism of the fungal cells such as Cryptococcus neoformans, Blastomyces dermatitidis, histoplasma capsulatum, Coccidioides, Sporothrix, Candida thus suppress it to grow.But Amphotericin B for injection has certain toxicity to cell, the present invention, through repeatedly experimental studies have found that, by controlling the concentration of amphotericin B, can reach and make it play a role but the object not affecting the activity of placenta mesenchyma stem cell.
Beneficial effect of the present invention:
(1) the present invention's whole process uses the reagent of serum-free animal origin-free and utilizes full-automatic tissue processor, substitute during traditional Human plactnta mescenchymal stem cell is cultivated use foetal calf serum, the trypsinase of animal-origin and collagenase, the potential danger that the reagent of animal serum and animal-origin brings can be avoided in clinical application;
(2) put into placenta protection liquid after gathering, the effect keeping in vitro tissue activity can be played, make manufacture have stronger operability, in 48 hours, be separated preparation, still can isolate active good placenta mesenchyma stem cell;
(3) placenta cleaning process is carried out except aseptically process except using the mycillin of wide spectrum, add amphotericin B and Metronidazule injection, to very effective with the umbilical cord process of mould, anerobe in birth process, can greatly reduce because mould, anerobe pollute the underproof probability of mescenchymal stem cell separation and Culture caused.
Embodiment
Embodiment 1
1. after placenta is given birth to; get the tissue block in 5cm around umbilical cord attachment area; join after the sodium chloride injection cleaning of 0.9% sodium chloride injection and 9g/L in placenta protection liquid in 2-8 DEG C of preservation; described placenta protection liquid joins in AIM-V substratum (treatment level) after benzylpenicillin sodium for injection and streptomycin sulphate for injection first being dissolved with a small amount of AIM-V substratum respectively, and wherein benzylpenicillin sodium and the final concentration of Vetstrep in placenta protection liquid are respectively 200U/mL and 200U/mL.So, placenta is put in placenta protection liquid and preserves in 2-8 DEG C of preservation, placenta can be made under the protection of placenta protection liquid all to can be used for separation in 48 hours and prepare mescenchymal stem cell.
2. the aseptic cleaning of Human plactnta
From placenta conserving liquid, take out Human plactnta with aseptic nipper and put into sterilising vessel, add 250mL 0.9% sodium chloride injection, with 8cm aseptic nipper, Human plactnta is shaken rinsing once back and forth.After with aseptic nipper, Human plactnta is transferred in another sterilising vessel again, add 250mL and face the sodium chloride solution (dense dual anti-solution) being respectively 3200U/mL, 4000U/mL with the benzylpenicillin sodium of newly joining and Vetstrep, shaken back and forth several times by Human plactnta with aseptic nipper every 1-2 minute, total immersion washes 10 minutes.With aseptic nipper, Human plactnta is picked up again, transfer in sterilising vessel and add every milliliter containing the Metronidazule injection of 50 unit Amphotericin B for injection, embathe 10 minutes in the same way.Embathe rear 8cm aseptic nipper to be picked up by Human plactnta, then put in another sterilising vessel, add 0.9% sodium chloride injection, and Human plactnta is shaken back and forth cleaning three times, the Human plactnta after cleaning is placed in disposable sterilized culture dish.
Above-mentioned dense dual anti-solution is for newly to join before use, and concrete compound method is: get each one of the streptomycin sulphate for injection of the benzylpenicillin sodium for injection of 800,000 units and 1,000,000 units and join in 250mL 0.9% sodium chloride injection and obtain.
Above-mentioned every milliliter of preparation containing the Metronidazule injection of 50U amphotericin B: the Amphotericin B for injection one getting 2.5 ten thousand units, adds 5mL 0.9% sodium chloride injection and dissolves, and then gets mixing in previous solu 1mL and 100mL Metronidazule injection and obtains.
To finally clean 0.9% sodium chloride injection draw samples of placenta and carry out the detection of microorganism situation through membrane-filter procedure: have no bacterium, mould-growth through 14 days culture sample.
3. the separation preparation of human placenta stem cell
Human plactnta 5cm aseptic nipper aseptically process in disposable sterilized culture dish crossed and scissors remove blood vessel wherein and mucous membrane, are then cut into meat gruel shape by 5cm sterile scissors.Get 10g at every turn and put C pipe (the supporting separator tube of full-automatic tissue processor), add 8mLAIM-V substratum, processing for 2 times as stirred under full-automatic tissue processor (C-01) program through the process of full-automatic separate tissue device, being then transferred in 50mL centrifuge tube; Use the same method the remaining meat gruel shape human placenta of process, until be all separated all people's placenta tissue.
Then after using 100 μm of aseptic strainer filterings of single use, obtain placenta tissue cell suspension, by placenta tissue cell suspension centrifugal 15min under 300g, abandon supernatant, collect lower confluent monolayer cells, be placed in 2 T25 culturing bottles respectively, after then adding serum free medium wherein, culturing bottle put 36 ~ 38 DEG C, saturated humidity, volume fraction be the CO of 5%
2cultivate in incubator.The quantity of culturing bottle can be selected according to the weight of process placenta, the Human plactnta that the reducible placement of general T25 culturing bottle is no more than 5g through the process of full-automatic separate tissue device, filtration, centrifugal after cell.The substratum that T25 culturing bottle adds is 6-8mL.
4. Human plactnta mescenchymal stem cell original cuiture
Cultivate after 5 days, not adherent upper strata is removed, then in culturing bottle, add serum free medium proceed to cultivate, and changed liquid once every 3-4 days, after about 10-15 days, adherent cell growth observed by available inverted microscope, then continue to cultivate, attached cell can be observed and be proliferated into larger cell colony gradually.When observing Tissue Culture Flask wall and forming multiple not of uniform size, cell island that cell quantity is intensive, namely obtain Human plactnta mescenchymal stem cell primary cell mixed solution, then through centrifugal, Human plactnta mescenchymal stem cell primary cell can be obtained.
5. Human plactnta mescenchymal stem cell goes down to posterity
Substratum in culturing bottle is shifted out completely, add in culturing bottle mass percent be 0.25% the tryptic phosphate buffered saline buffer of recombinant animal (T25 adds 3mL, T75 adds 4mL, T175 adds 6mL), then put into 36 ~ 38 DEG C of incubator insulations and digest about 7-9 minute, the contracting of attached cell circle is observed in the process under inverted microscope, and cell to have departed from bottle at the bottom of after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, count cytoactive with on binocular microscope with tally counting and trypan blu e dyeing thereof.Then centrifuge tube is put centrifugal 5min under 300g condition, after centrifugal, abandon supernatant, blow the even cell be deposited in bottom centrifuge tube gently with Pasteur's pipe, then according to 4000-6000 cell count/cm
2be inoculated in culturing bottle, and carry out mark, in culturing bottle, supplement serum free medium, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once.When after cultivation 24h, passage cell starts adherent, becomes single dispersion long strip shape cell, changes liquid can remove non-attached cell after 3-4 days by full dose, and now cell is the spindle shape cell that degrees of fusion reaches about 50%.After about 6 days, cell based instinct reaches the fusion of more than 80%, mescenchymal stem cell, then can repeat aforesaid operations as required and carry out P2, P3, P4 ... go down to posterity.
Embodiment 2
1. after placenta is given birth to; get the tissue block in 3cm around umbilical cord attachment area; join after 0.9% sodium chloride injection cleaning in placenta protection liquid in 2-8 DEG C of preservation; described placenta protection liquid is add benzylpenicillin sodium and Vetstrep in AIM-V substratum (treatment level), and wherein benzylpenicillin sodium and the final concentration of Vetstrep in placenta protection liquid are respectively 100U/mL and 100U/mL.So, placenta is put in placenta protection liquid and preserves in 2-8 DEG C of preservation, placenta can be made under the protection of placenta protection liquid all to can be used for separation in 48 hours and prepare mescenchymal stem cell.
2. the aseptic cleaning of Human plactnta
From placenta conserving liquid, take out Human plactnta with aseptic nipper and put into sterilising vessel, add 0.9% sodium chloride injection, with 8cm aseptic nipper, Human plactnta is shaken rinsing once back and forth.After with aseptic nipper, Human plactnta is transferred in another sterilising vessel again, add the sodium chloride solution (dense dual anti-solution) facing and be respectively 2500U/mL, 3500U/mL with the benzylpenicillin sodium of newly joining and Vetstrep, shaken back and forth several times by Human plactnta with aseptic nipper every 1-2 minute, total immersion washes 8 minutes.With aseptic nipper, Human plactnta is picked up again, transfer in sterilising vessel and add every milliliter containing the Metronidazule injection of 30U amphotericin B, embathe 8 minutes in the same way.Embathe rear 8cm aseptic nipper to be picked up by Human plactnta, then put in another sterilising vessel, add 0.9% sodium chloride injection, and Human plactnta is shaken back and forth cleaning three times, the Human plactnta after cleaning is placed in disposable sterilized culture dish.
Above-mentioned dense dual anti-solution is for newly to join before use, and it is preparation and every milliliter of compound method reference example 1 containing the Metronidazule injection of 30U Amphotericin B for injection specifically.
To finally clean 0.9% sodium chloride injection draw samples of placenta and carry out the detection of microorganism situation through membrane-filter procedure: have no bacterium, mould-growth through 14 days culture sample.
3. the separation preparation of human placenta stem cell
Human plactnta 5cm aseptic nipper aseptically process in disposable sterilized culture dish crossed and scissors remove blood vessel wherein and mucous membrane, are then cut into meat gruel shape by 5cm sterile scissors.Get 10g at every turn and put C pipe (the supporting separator tube of full-automatic tissue processor), add 8mL AIM-V substratum, through the process of full-automatic separate tissue device, be then transferred in 50mL centrifuge tube; Use the same method the remaining meat gruel shape human placenta of process, until be all separated all people's placenta tissue.
Then after using the aseptic strainer filtering of single use, obtain placenta tissue cell suspension, by centrifugal for placenta tissue cell suspension, abandon supernatant, collect lower confluent monolayer cells, be placed in culturing bottle, after then adding serum free medium wherein, culturing bottle put 36 ~ 38 DEG C, saturated humidity, volume fraction be the CO of 5%
2cultivate in incubator.
4. Human plactnta mescenchymal stem cell original cuiture
Cultivate after 5-6 days, not adherent upper strata is removed, then in culturing bottle, add serum free medium proceed to cultivate, and changed liquid once every 3-4 days, after about 10-15 days, adherent cell growth observed by available inverted microscope, then continue to cultivate, attached cell can be observed and be proliferated into larger cell colony gradually.When observing Tissue Culture Flask wall and forming multiple not of uniform size, cell island that cell quantity is intensive, namely obtain Human plactnta mescenchymal stem cell primary cell mixed solution, then through centrifugal, Human plactnta mescenchymal stem cell primary cell can be obtained.
5. Human plactnta mescenchymal stem cell goes down to posterity
Substratum in culturing bottle is shifted out completely, the tryptic phosphate buffered saline buffer of recombinant animal that mass percent is 0.25% is added in culturing bottle, then put into 36 ~ 38 DEG C of incubator insulations and digest about 7-9 minute, the contracting of attached cell circle is observed in the process under inverted microscope, and cell to have departed from bottle at the bottom of after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, count cytoactive with on binocular microscope with tally counting and trypan blu e dyeing.Then centrifuge tube is centrifugal, abandon supernatant, blow the even cell be deposited in bottom centrifuge tube gently with Pasteur's pipe, then according to 4000-6000 cell count/cm
2be inoculated in culturing bottle, and carry out mark, supplement serum free medium in culturing bottle, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once.When after cultivation 24h, passage cell starts adherent, becomes single dispersion long strip shape cell, changes liquid can remove non-attached cell after 3-4 days by full dose, and now cell is the spindle shape cell that degrees of fusion reaches about 50%.After about 6 days, cell based instinct reaches the fusion of more than 80%, mescenchymal stem cell, then can repeat aforesaid operations as required and carry out P2, P3, P4 ... go down to posterity.
The mescenchymal stem cell that embodiment 1 and 2 obtains is carried out FCM analysis, detection method and the results are shown in down:
Experimental principle: utilize Flow Cytometry to detect fluorescent-labeled antibody.According to antigen-antibody combination principle, with the antibody of specific fluorescent element mark, the known cell carrying corresponding antigens is dyeed.Cell through fluorescein labelled antibody dyeing can by flow cytometer identification, and the intensity of fluorescein entrained by known cell, carry out qualitative to traget antibody, quantitative analysis.
Detecting step:
(1) get 5 streaming pipes, be labeled as control tube 1. FITC/PE/APC 2. FITC/PE sample tube 3. 90/34/14 4. DR/105/19 5. 45/34 respectively.
(2) each streaming pipe adds passage cell (number of nucleated cells 2-5 × 10 of identical amount respectively
5individual), can not tube wall be adhered to.
(3) 1. control tube adds Mouse IgG2a-PE, Mouse IgG1-FITC, Mouse IgG1-APC 5 ul respectively, mixing; 2. control tube adds Mouse IgG2a-PE, Mouse IgG1-FITC 5 ul respectively, mixing; 3. sample tube adds CD90-FITC, CD73-PE, CD14-APC 5 ul respectively, mixing; 4. sample tube adds DR-FITC, CD105-PE, CD19-APC 5 ul respectively, mixing; 5. sample tube adds CD45-FITC, CD34-PE 5 ul respectively, mixing.
(4) room temperature lucifuge places 15min, adds 2mL PBS/ and manages, 1400 rpm/min, centrifugal 5min.
(5) supernatant, upsprings pipe inner cell, adds 0.5mL PBS, mixing, upper machine testing (if can not go up machine in time, should add paraformaldehyde and fix).
(6) upper machine analytical results obtains: CD73, CD90, CD105 are greater than 95%, are the positive; CD14, CD19, CD34, CD4,5HLA-DR are less than 2%, are feminine gender.
Above-mentioned explanation: the Human plactnta mescenchymal stem cell obtained according to the method separation and Culture in embodiment, meets CD73, CD90, CD105 and be greater than 95% is the positive; CD14, CD19, CD34, CD4,5HLA-DR are less than 2%, are the result of feminine gender, through being accredited as mescenchymal stem cell.
The membrane-filter procedure used in above-mentioned Sterility testing process is as follows:
Sterility Test comprises than membrane-filter procedure and direct inoculation, and membrane-filter procedure can avoid effectively removing microbiotic and other water-soluble substanceses to the interference of Sterility testing, can reflect the state that in cell cultivation process, microorganism exists more accurately.
The Sterility testing of the present embodiment is adopted and is detected according to " Chinese Pharmacopoeia 2010 editions " membrane-filter procedure, adopts HTY-601 germ collector and APY serial culture device.The whole process of Sterility testing all under environment cleanliness 10000 grades local cleanliness factor 100 grades way flow air section in carry out, its whole process strictly observes aseptic technique, prevents microbial contamination.The cleanliness factor of isolated system internal medium meets the requirement of sterility test.
Concrete implementation step is as follows:
(1) take out incubator and first check whether packaging stands intact.Inspection filter sizes should be not more than 0.45 μm, and diameter is about 50mm.Filter membrane material is selected according to trial-product characteristic, should through suitable method sterilizing before filter and filter membrane use.During use, the integrity after filter membrane before filtration should be ensured.
(2) inserted one by one in stainless steel seat by incubator, the elastic hose of incubator is loaded germ collector pump head, note accurate positioning, flexible pipe tendency is smooth and easy.
(3) wetting filter membrane: select the sodium-chlor-peptone buffer agent of PH7.0 as washing fluid, washes geramine with 75% ethanol or 0.2% and carefully carries out disinfection at (position of particularly container top needs puncture) to the cleaning liquid bottle surface of band plug, dry.Then supravasal for incubator syringe needle is inserted in washing fluid container plug, open germ collector, adjusting rotary speed is 160RMP, being inverted cleaning liquid bottle after starting about 3 seconds and being placed in carries on bottle stand, about 50ml washing fluid is injected in every cup, wetting filter membrane (wetting liquid is without the need to being filtered dry), takes off cleaning liquid bottle and stands in operating table surface, stop germ collector after evacuation of liquid.
(4) dilution of trial-product, transfer, filtration: wash geramine with 75% ethanol or 0.2% and carefully sample hose dress trial-product surface is carried out disinfection, dry.Open the lid of sample hose, sample pipe shaft is held with 45 DEG C of angles, then supravasal for incubator syringe needle is inserted to the bottom of sample hose, open germ collector, adjusting rotary speed is 160RMP, to be transferred to by test liquid in cup and to filter, treat test liquid discharge to the greatest extent, stop germ collector.
(5) rinse: the elasticity helmet taking off cup filter bowl upper port.Inserted by syringe needle in cleaning liquid bottle, open germ collector, adjusting rotary speed is 160RMP, then is inverted by cleaning liquid bottle, injects about about 100mL washing fluid, rinse 3 times in every cup.Take off red helmet pressure release after flushing completes, use yellow cap stopper to close liquid outlet (rotation push-tight), then substratum is reentered in sump pit.Pay special attention to: when rinsing, not advising carrying out excessive jolting to cup, otherwise causing washing fluid to enter air filter.
(6) substratum is added:
An other pipe of incubator four-way and location buckle is clamped with red intermediate plate.Start germ collector with 100R rotating speed, then be inverted medium bottle, make all THIOGLYCOLLIC ACID salt fluid media transfer in incubator cup.First clamp another two pipes with green intermediate plate, more red intermediate plate is taken away, inject improvement Martin substratum, equipment operation is with adding THIOGLYCOLLIC ACID salt broth.When two cups fill it up with substratum entirely, clamp the flexible pipe from 2 ~ 3cm place above incubator cup with corresponding intermediate plate, cut two flexible pipes simultaneously, leave 5 ~ 6cm, and other end is inserted the air filter place of cup.(scissors needed spirit lamp flame)
(7) get corresponding washing fluid to operate with method, as negative control.
(8) colony culture device containing substratum of end of operation is shifted out sterilisable chamber, get one pipe and make positive control, add corresponding contrast bacterium liquid according to Positive contrast bacteria selection principle.
(9) THIOGLYCOLLIC ACID salt broth is cultivated 14 days at 30 ~ 35 DEG C, and improvement Martin substratum is cultivated 14 days at 23 ~ 28 DEG C.Day by day should check whether bacteria growing between incubation period, and fill in sterility test record.As muddy or precipitation appears in trial-product pipe, when can not judge from outward appearance after cultivating, this nutrient solution desirable is seeded in another identical fresh culture, microbial culture 2 days, fungus culture 3 days, and whether the fresh culture of the same race observing inoculation occurs muddiness again; Or get nutrient solution smear, dyeing, microscopy, has judged whether bacterium.
(10) result judges: well-grown answered by positive control pipe, and negative control pipe must not have bacteria growing.Otherwise, invalidate the test.
If trial-product pipe is all clarified, though or aobvious muddy through confirmation asepsis growth, sentence trial-product and conform with the regulations; If any aobvious muddiness is also confirmed in trial-product pipe bacteria growing, sentence trial-product against regulation, unless energy sufficient proof experimental result is invalid, contained by the non-trial-product of the microorganism namely grown.When meeting at least one condition following, can test-results be sentenced invalid:
1. the microorganism monitored results of sterility test test equipment used and environment does not meet sterility test requirement;
2. look back sterility test process, find that there is the factor that may cause microbial contamination;
2. the microorganism grown in trial-product pipe is after qualification, and confirmation is article because using in sterility test and (or) aseptic technique is improper causes.If it is invalid through confirming to test, answer retry.During retry, again getting with measuring trial-product, checking in accordance with the law, if asepsis growth, sentencing trial-product and conform with the regulations; If there is bacteria growing, sentence trial-product against regulation.
Claims (5)
1. a method for cultivator placenta mesenchyma stem cell, is characterized in that: it comprises the steps:
(1) human placenta of fresh collection is got, cleaning, put into placenta protection liquid 2-8 DEG C to save backup, described placenta protection liquid adds benzylpenicillin sodium in AIM-V substratum and Vetstrep obtains, and wherein benzylpenicillin sodium and the final concentration of Vetstrep in placenta protection liquid are respectively 100-200 U/mL and 100-200 U/mL;
(2) human placenta being immersed in and being no more than 48 hours in placenta protection liquid is got, cleaning, put successively again face be respectively the sodium chloride solution of 2500-3500 U/mL and 3500-4500 U/mL with the benzylpenicillin sodium of newly joining and Vetstrep content and every milliliter embathe containing in the Metronidazule injection of 30-50 U amphotericin B, finally again cleaning be placed on carry out in disposable sterilized culture dish for subsequent use;
(3) aseptic cleaned human placenta is cut into meat gruel shape, adds AIM-V substratum, put in separator tube and be separated with full-automatic separate tissue device, re-use aseptic strainer filtering, obtain placenta tissue cell suspension;
(4) placenta tissue cell suspension is carried out centrifugal, abandon supernatant, collect lower floor, be placed in culturing bottle, then add serum free medium wherein, be placed in 36-38 DEG C, saturated humidity, volume fraction be the CO of 5%
2cultivate in incubator, cultivate after 5-6 days, not adherent upper strata is removed, then in culturing bottle, add serum free medium continue to cultivate, and changed liquid once every 3-4 days, after cultivation 10-15 days, to observe bottle wall is formed multiple not of uniform size, during the intensive cell island of cell quantity, then obtain Human plactnta mescenchymal stem cell primary cell mixed solution, then through centrifugal, Human plactnta mescenchymal stem cell primary cell can be obtained, then the substratum in culturing bottle is shifted out completely, the recombinant animal tryptic phosphate buffered saline buffer submergence attached cell that mass percent is 0.25% is added in culturing bottle, put into 36 ~ 38 DEG C of incubator insulation digestion 7-9 minute, when observing the contracting of attached cell circle, and at the bottom of having departed from bottle after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, centrifugally abandon supernatant, blow the even cell be deposited in bottom centrifuge tube, again according to 4000-6000 cell/cm
2be inoculated in culturing bottle, and supplement serum free medium in culturing bottle, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once, fusion together to attached cell, and degrees of fusion reaches 80-90%, obtains Human plactnta mescenchymal stem cell, whenever necessary, repeats aforesaid operations and carries out how increasing for cell cultures.
2. the method for cultivator placenta mesenchyma stem cell according to claim 1, is characterized in that: join in treatment level AIM-V substratum after benzylpenicillin sodium for injection and streptomycin sulphate for injection dissolve by placenta protection liquid in described step (1) in advance again and obtain; Benzylpenicillin sodium for injection and streptomycin sulphate for injection are mixed to get by a certain amount of adding in 0.9% sodium chloride injection by the sodium chloride solution that the middle benzylpenicillin sodium of described step (2) and Vetstrep content are respectively 2500-3500 U/mL and 3500-4500 U/mL; Described every milliliter of preparation of Metronidazule injection containing 30-50 U amphotericin B is by Amphotericin B for injection first with after 0.9% sodium chloride injection dissolving, then is mixed to get with a certain amount of Metronidazule injection; Described Human plactnta benzylpenicillin sodium and Vetstrep content be respectively the sodium chloride solution of 2500-3500 U/mL and 3500-4500 U/mL and every milliliter be 8-12min containing the time of embathing in the Metronidazule injection of 30-50 U amphotericin B.
3. the method for cultivator placenta mesenchyma stem cell according to claim 1, is characterized in that: the cleaning in described step (1) and step (2) is 0.9% sodium chloride injection cleaning.
4. the method for cultivator placenta mesenchyma stem cell according to claim 1, is characterized in that: the placenta tissue in described step (1) gets after placenta gives birth to, and gets the tissue block in 3-5cm around umbilical cord attachment area.
5. the method for cultivator placenta mesenchyma stem cell according to claim 1, is characterized in that: T25 culturing bottle can place the Human plactnta that is no more than 5g through the process of full-automatic separate tissue device, filtration, centrifugal after lower confluent monolayer cells cultivate; The T75 culturing bottle Human plactnta that can place 10-15 g through the process of full-automatic separate tissue device, filtration, centrifugal after lower confluent monolayer cells cultivate; The T175 culturing bottle Human plactnta that can place 30-35 g through the process of full-automatic separate tissue device, filtration, centrifugal after lower confluent monolayer cells cultivate; The volume of the serum free medium needed in T25 culturing bottle is 6-8mL; The volume of the serum free medium needed in T75 culturing bottle is 20-25mL; The volume of the serum free medium needed in T175 culturing bottle is 30-35mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310579777.3A CN103555664B (en) | 2013-11-19 | 2013-11-19 | A kind of method of cultivator placenta mesenchyma stem cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310579777.3A CN103555664B (en) | 2013-11-19 | 2013-11-19 | A kind of method of cultivator placenta mesenchyma stem cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103555664A CN103555664A (en) | 2014-02-05 |
| CN103555664B true CN103555664B (en) | 2015-11-04 |
Family
ID=50010024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310579777.3A Active CN103555664B (en) | 2013-11-19 | 2013-11-19 | A kind of method of cultivator placenta mesenchyma stem cell |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103555664B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106172373B (en) * | 2016-07-14 | 2019-04-19 | 金华市思丹姆干细胞生物科技有限公司 | Preparation method of placenta preservation solution |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1746297A (en) * | 2004-09-09 | 2006-03-15 | 中国人民解放军军事医学科学院基础医学研究所 | Placenta derived mesenchymal stem cell and preparation thereof |
| CN101657206A (en) * | 2007-02-12 | 2010-02-24 | 人类起源公司 | Treatment of inflammatory diseases using placental stem cells |
| CN102676454A (en) * | 2012-05-16 | 2012-09-19 | 北京和泽普瑞生物科技有限公司 | Preparation method for CIK (cytokine induced killer) cell of umbilical cord blood source |
| CN103239479A (en) * | 2013-03-19 | 2013-08-14 | 邱启裕 | Animal model establishment method of human primary skin squamous epithelial cell cancer stem cell |
-
2013
- 2013-11-19 CN CN201310579777.3A patent/CN103555664B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1746297A (en) * | 2004-09-09 | 2006-03-15 | 中国人民解放军军事医学科学院基础医学研究所 | Placenta derived mesenchymal stem cell and preparation thereof |
| CN101657206A (en) * | 2007-02-12 | 2010-02-24 | 人类起源公司 | Treatment of inflammatory diseases using placental stem cells |
| CN102676454A (en) * | 2012-05-16 | 2012-09-19 | 北京和泽普瑞生物科技有限公司 | Preparation method for CIK (cytokine induced killer) cell of umbilical cord blood source |
| CN103239479A (en) * | 2013-03-19 | 2013-08-14 | 邱启裕 | Animal model establishment method of human primary skin squamous epithelial cell cancer stem cell |
Non-Patent Citations (3)
| Title |
|---|
| 人脐带血间充质干细胞的体外培养及其影响因素(英文);黄伟等;《中国组织工程研究与临床康复》;20070114(第03期);572-575 * |
| 犬骨髓间叶干细胞的分离培养和生物学特性;张澍等;《中华心律失常学杂志》(第01期);摘要 * |
| 胶质细胞源性神经营养因子联合转化生长因子β1体外诱导大鼠脊髓源性神经干细胞的分化(英文);高明勇等;《中国组织工程研究与临床康复》;20070617(第24期);摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103555664A (en) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103451151B (en) | A kind of method of cultivator umbilical cord mesenchymal stem cells | |
| CN105861430B (en) | A kind of excretion body, the preparation method of excretion body and its application in preparation treatment medication for treating pyemia or preparation | |
| CN101914490B (en) | Human amnion mesenchymal stem cell serum-free culture medium and culture method thereof | |
| CN105713871A (en) | Human chorion mesenchymal stem cell isolated culture method | |
| CN101984049B (en) | Method for separating mesenchymal stem cells from dispose tissues | |
| WO2004011593A1 (en) | Automatic culture apparatus for cell or tisse with biological origin | |
| CN100384987C (en) | Method for expanding hemopoietic stem cell under three-dimensional condition | |
| CN106754676B (en) | Composition for protecting adipose tissue and preparation method and application thereof | |
| CN102485885A (en) | Separating method and application of fat stem cells | |
| CN107177546A (en) | A kind of preparation method of type I collagen culture medium and type I collagen | |
| CN108315297A (en) | A method of it detached from adipose tissue, purify fat stem cell | |
| CN110623917A (en) | Beautifying and skin repairing sodium hyaluronate gel coated with stem cell complex factor | |
| CN103555663B (en) | Method for cultivating human amniotic mesenchymal stem cells | |
| CN108642002A (en) | A kind of method of serum-free domestication culture human mesenchymal stem cell | |
| JP2019216694A (en) | Hollow fiber cell culture device, cell culture method, production method of culture supernatant | |
| CN107502588A (en) | A kind of method that separation prepares dental pulp stem cell | |
| CN103555664B (en) | A kind of method of cultivator placenta mesenchyma stem cell | |
| CN103756965B (en) | A kind of method of lavation hemopoietic stem cell from placenta | |
| CN108949682A (en) | A kind of preparation, culture and the purification process of dental pulp mescenchymal stem cell | |
| CN108865985A (en) | A kind of method of the pre- epithelial-mesenchymal conversion of stem cell source excretion soma | |
| CN104388391B (en) | Mice paneth's cell hybridoma cell strain, preparation method and applications | |
| CN106754679A (en) | A kind of method of cell culture medium and culture amnion mesenchymal stem cell | |
| CN106497863A (en) | A kind of separation of cornea of rats endothelial cell, purifying and cultural method | |
| CN102796701A (en) | Method for amplifying human umbilical cord mesenchymal stem cells through in-vitro 3D stent-free suspension cultivation | |
| CN101412987A (en) | Method for amplifying in vitro mesenchymal stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |